MNKD

Company Overview — What Does MANNKIND CORP Do?

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. MANNKIND CORP (MNKD) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael E. Castagna and employs approximately 400 people, headquartered in VALENCIA, Connecticut. With a market capitalization of $783M, MNKD is one of the notable companies in the Healthcare sector.

MANNKIND CORP (MNKD) Stock Rating — Reduce (April 2026)

As of April 2026, MANNKIND CORP receives a Reduce rating with a composite score of 40.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MNKD ranks #3,444 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MANNKIND CORP ranks #535 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MNKD Stock Price and 52-Week Range

MANNKIND CORP (MNKD) currently trades at $2.60. The stock gained $0.04 (1.6%) in the most recent trading session. The 52-week high for MNKD is $6.51, which means the stock is currently trading -60.1% from its annual peak. The 52-week low is $2.57, putting the stock 1.2% above its annual trough. Recent trading volume was 1.3M shares, reflecting moderate market activity.

Is MNKD Overvalued or Undervalued? — Valuation Analysis

MANNKIND CORP (MNKD) carries a value factor score of 53/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 23.73x, compared to the Healthcare sector average of 23.63x — a premium of 0%. The price-to-sales ratio is 2.58x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MNKD trades at 16.95x EV/EBITDA, versus 6.34x for the sector.

Overall, MNKD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

MANNKIND CORP Profitability — ROE, Margins, and Quality Score

MANNKIND CORP (MNKD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -23.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 4.2% versus the sector average of -33.1%.

On a margin basis, MANNKIND CORP reports gross margins of 94.8%, compared to 71.5% for the sector. The operating margin is 19.1% (sector: -66.1%). Net profit margin stands at 11.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 13.5% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

MNKD Debt, Balance Sheet, and Financial Health

MANNKIND CORP has a debt-to-equity ratio of -246.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.70x, suggesting adequate working capital coverage. Total debt on the balance sheet is $355M. Cash and equivalents stand at $127M.

MNKD has a beta of 0.57, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for MANNKIND CORP is 46/100, reflecting average volatility within the normal range for its sector.

MANNKIND CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, MANNKIND CORP reported revenue of $307M and earnings per share (EPS) of $0.02. Net income for the quarter was $33M. Gross margin was 94.8%. Operating income came in at $59M.

In FY 2025, MANNKIND CORP reported revenue of $349M and earnings per share (EPS) of $0.02. Net income for the quarter was $6M. Gross margin was 92.3%. Revenue grew 22.2% year-over-year compared to FY 2024. Operating income came in at $39M.

In Q3 2025, MANNKIND CORP reported revenue of $82M and earnings per share (EPS) of $0.03. Net income for the quarter was $8M. Gross margin was 94.5%. Revenue grew 17.2% year-over-year compared to Q3 2024. Operating income came in at $19M.

In Q2 2025, MANNKIND CORP reported revenue of $77M and earnings per share (EPS) of $0.00. Net income for the quarter was $668,000. Gross margin was 94.0%. Revenue grew 5.7% year-over-year compared to Q2 2024. Operating income came in at $5M.

Over the past 8 quarters, MANNKIND CORP has demonstrated a growth trajectory, with revenue expanding from $72M to $307M. Investors analyzing MNKD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MNKD Dividend Yield and Income Analysis

MANNKIND CORP (MNKD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MNKD Momentum and Technical Analysis Profile

MANNKIND CORP (MNKD) has a momentum factor score of 15/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

MNKD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MANNKIND CORP (MNKD) ranks #535 out of 838 stocks based on the Blank Capital composite score. This places MNKD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MNKD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MNKD vs S&P 500 (SPY) comparison to assess how MANNKIND CORP stacks up against the broader market across all factor dimensions.

MNKD Next Earnings Date

No upcoming earnings date has been announced for MANNKIND CORP (MNKD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MNKD? — Investment Thesis Summary

The quantitative profile for MANNKIND CORP suggests caution. Momentum is weak at 15/100, a headwind for near-term performance.

In summary, MANNKIND CORP (MNKD) earns a Reduce rating with a composite score of 40.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MNKD stock.

Related Resources for MNKD Investors

Explore more research and tools: MNKD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MNKD head-to-head with peers: MNKD vs AZN, MNKD vs SLGL, MNKD vs VMD.